About GBSciences
GBSciences is a company based in Las Vegas (United States) founded in 1967.. The company has 2 employees as of March 31, 2023. GBSciences offers products and services including PhAROS Drug Discovery Platform, Parkinson’s Disease Therapies, and COVID-Related Therapies. GBSciences operates in a competitive market with competitors including Tenaya Therapeutics, Cellino, Arrakis Therapeutics, MyoKardia and Eiger BioPharmaceuticals, among others.
- Headquarter Las Vegas, United States
- Employees 2 as on 31 Mar, 2023
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Gb Sciences, Inc.
-
Annual Revenue
$00as on Mar 31, 2023
-
Net Profit
$-1.36 M66.99as on Mar 31, 2023
-
EBITDA
$-1.42 M11.84as on Mar 31, 2023
-
Latest Funding Round
$75 K (USD), Post-IPO
Aug 02, 2023
-
Investors
-
Employee Count
2
as on Mar 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of GBSciences
GBSciences is a publicly listed company on the OTC with ticker symbol GBLX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of GBSciences
GBSciences offers a comprehensive portfolio of products and services, including PhAROS Drug Discovery Platform, Parkinson’s Disease Therapies, and COVID-Related Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
AI platform for identifying effective drug combinations from plants.
Formulations for treating Parkinson's with plant-based mixtures.
Treatments to suppress hyperinflammation from COVID infections.
Unlock access to complete
Unlock access to complete
Funding Insights of GBSciences
- Total Funding Total Funding
- Total Rounds 11
- Last Round Post-IPO — $75,000
-
First Round
First Round
(01 Apr 2014)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2023 | Amount | Post-IPO - GBSciences | Valuation |
investors |
|
| Jun, 2022 | Amount | Post-IPO - GBSciences | Valuation |
investors |
|
| Oct, 2019 | Amount | Post-IPO - GBSciences | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by GBSciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - GBSciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Gbsciences Comparisons
Competitors of GBSciences
GBSciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Cellino, Arrakis Therapeutics, MyoKardia and Eiger BioPharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| domain | founded_year | HQ Location |
Developer of autologous cell therapies
|
|
| domain | founded_year | HQ Location |
Provider of tools for the analysis of RNA structures
|
|
| domain | founded_year | HQ Location |
Specialized drugs are developed for genetic heart diseases.
|
|
| domain | founded_year | HQ Location |
Developer of antiviral agents against targets in the treatment of hepatitis
|
|
| domain | founded_year | HQ Location |
Therapeutics for heart and cardiovascular diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Gbsciences
Frequently Asked Questions about GBSciences
When was GBSciences founded?
GBSciences was founded in 1967 and raised its 1st funding round 47 years after it was founded.
Where is GBSciences located?
GBSciences is headquartered in Las Vegas, United States. It is registered at Las Vegas, Nevada, United States.
Who is the current CEO of GBSciences?
John Claybron Poss is the current CEO of GBSciences.
How many employees does GBSciences have?
As of Mar 31, 2023, the latest employee count at GBSciences is 2.
What does GBSciences do?
Founded in 1967 and headquartered in Las Vegas, United States, cannabinoid therapeutics are developed by the company for cardiovascular conditions, neurodegenerative diseases, inflammatory disorders, heart issues, and chronic pain. Proprietary formulations are included in the pipeline to address these areas within the biotechnology sector. Operations focus on research and development of targeted treatments.
Who are the top competitors of GBSciences?
GBSciences's top competitors include Esperion Therapeutics, Tenaya Therapeutics and Cellino.
What products or services does GBSciences offer?
GBSciences offers PhAROS Drug Discovery Platform, Parkinson’s Disease Therapies, and COVID-Related Therapies.
Is GBSciences publicly traded?
Yes, GBSciences is publicly traded on OTC under the ticker symbol GBLX.
What is GBSciences's ticker symbol?
The ticker symbol of GBSciences is GBLX on OTC.